Shopping Cart
Remove All
Your shopping cart is currently empty
Ex26 (S1P1-IN-Ex26) is a selective and potent sphingosine 1-phosphate receptor 1 (S1P1) antagonist that disrupts SR-B1-S1PR1 interactions and inhibits S1P-S1PR1 signaling. Ex26 is used in experimental autoimmune encephalomyelitis, atherosclerosis, and gastric cancer.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $113 | In Stock | In Stock | |
| 5 mg | $283 | In Stock | In Stock | |
| 10 mg | $455 | In Stock | In Stock | |
| 25 mg | $733 | In Stock | In Stock | |
| 50 mg | $987 | In Stock | In Stock | |
| 100 mg | $1,360 | - | In Stock |
| Description | Ex26 (S1P1-IN-Ex26) is a selective and potent sphingosine 1-phosphate receptor 1 (S1P1) antagonist that disrupts SR-B1-S1PR1 interactions and inhibits S1P-S1PR1 signaling. Ex26 is used in experimental autoimmune encephalomyelitis, atherosclerosis, and gastric cancer. |
| Targets&IC50 | S1P1:0.93 nM |
| In vitro | In U2OS cells and Chinese hamster ovary cells, Ex26 (0-10 μM; 1 hour) was confirmed as a potent and selective antagonist of S1P1 (IC50=0.93 nM)[1]. |
| In vivo | In eight-week-old male C57Bl/6J mice, S1P1-IN-Ex26 (3 mg/kg; intraperitoneal injection; once daily; 3 days) induced lymphocyte sequestration at low doses, with an ED50 of 0.06 mg/kg after 2 hours of treatment. This led to significant retention of T and B cells within the lymph nodes and significant decreases in T and B cells within the spleen[1]. |
| Synonyms | S1P1-IN-Ex26 |
| Molecular Weight | 494.99 |
| Formula | C28H28ClFN2O3 |
| Cas No. | 1233332-37-0 |
| Smiles | O=C(O)C1(NC(=O)C2=C(C=C(C=C2C)C=3C=C(C=CC3F)NC(C4=CC=C(Cl)C(=C4)C)C)C)CC1 |
| Relative Density. | no data available |
| Color | White |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.